

Additional file 4. Efficacy in Evaluable Patients by PD-L1 Expression Status (cutoff: expression in $\geq 5\%$ of tumor cells; N=214)

	PD-L1+ (n=84)	PD-L1- (n=130)
Confirmed ORR (95% CI), %	23.8 (15.2-34.3)	12.3 (7.2-19.2)
Median PFS (95% CI), months	2.2 (1.4-4.11)	1.5 (1.4-2.4)
3-month PFS rate (95% CI), %	34.0 (25.8-42.4)	43.4 (32.3-53.9)
6-month PFS rate (95% CI), %	22.6 (15.5-30.5)	35.1 (24.7-45.7)
12-month PFS rate (95% CI), %	14.6 (8.8-21.9)	23.9 (14.2-35.0)
Median OS (95% CI), months	8.41 (6.0-11.3)	6.5 (5.3-10.1)
6-month OS rate (95% CI), %	61.5 (50.2-71.0)	53.4 (44.4-61.6)
12-month OS rate (95% CI), %	39.4 (28.8-49.7)	36.9 (28.6-45.2)
24-month OS rate (95% CI), %	24.3 (15.6-34.0)	17.9 (11.8-25.0)

ORR, objective response rate; OS, overall survival;
PFS, progression-free survival; PD-L1,
programmed cell death 1 ligand 1.